Axcella
840 Memorial Drive
Entrance on Blackstone Street, Third Floor
Cambridge
Massachusetts
02139
United States
Tel: 857-320-2200
Fax: 617-441-6243
Website: http://www.axcellahealth.com/
Email: info@axcellahealth.com
About Axcella
Axcella Health is pioneering revolutionary new medicines with a focus on amino acid homeostasis. The company has discovered more than 2,000 diseases with amino acid imbalances and developed a systems pharmacology approach to restore health at the cellular level. Axcella’s proprietary platform is clinically validated across several indication areas, with clinical-stage candidates in muscle, neurodegenerative and liver conditions. Axcella is led by a team with a strong track record of leaving a lasting impact on the therapeutic landscape through the development of novel products. The company was founded by VentureLabs, the Innovation Foundry at Flagship Ventures, and has received additional funding from Fidelity Research & Management Group, Gurnet Point Capital and Nestlé Health Science. Axcella is based in Cambridge, Mass.YEAR FOUNDED:
2010
LEADERSHIP:
CEO: Robert Connelly
CMO: Christopher I. Wright
CFO: Thomas Leggett
JOBS:
Please click here for Axcella job opportunities.
85 articles with Axcella
-
Axcella Reports First Quarter 2022 Financial Results and Provides Business Update
5/5/2022
Axcella Therapeutics, a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator compositions, announced financial results for the first quarter ended March 31, 2022 and provided a business update.
-
Axcella Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
3/30/2022
Axcella Therapeutics today announced financial results for the fourth quarter and full year ended December 31, 2021 and provided a business update.
-
Although some may be hopeful that the end of the COVID-19 pandemic is nearby, millions still are facing their own lifelong version of the pandemic.
-
Axcella to Report Fourth Quarter and Year End 2021 Financial Results on March 30, 2022
3/23/2022
Axcella Therapeutics today announced that it plans to report its fourth quarter and year end 2021 financial results and other business updates on March 30, 2022.
-
Axcella Therapeutics Announces $25 Million Registered Direct Offering of Common Stock Priced At The Market
3/16/2022
Axcella Therapeutics today announced that it has entered into a securities purchase agreement with investors in a registered direct offering of 13,089,002 shares of common stock (the “Shares”) at a purchase price of $1.91 per share.
-
Axcella Therapeutics Announces FDA Fast Track Designation for AXA1125 in NASH
2/14/2022
Axcella Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted a Fast Track Designation to AXA1125 for the treatment of non-alcoholic steatohepatitis (NASH) with liver fibrosis.
-
Axcella Therapeutics Announces Appointment of New Chief Financial Officer
2/7/2022
Axcella Therapeutics today announced the appointment of Robert Crane as the company’s new Chief Financial Officer.
-
Axcella Therapeutics Announces Initiation of AXA1125 Long COVID Phase 2a Clinical Trial
12/16/2021
Axcella Therapeutics today announced that patient screening is now underway in a Phase 2a trial that is investigating AXA1125, an oral product candidate, as a potential treatment for Long COVID, also known as Post COVID-19 Condition and post-acute sequelae of SARS-COV-2 infection (PASC).
-
Axcella Therapeutics Promotes Margaret Koziel, M.D., to Chief Medical Officer
12/6/2021
Axcella Therapeutics today announced that Margaret Koziel, M.D., has been promoted to the role of Chief Medical Officer and added as a member of the company’s executive team.
-
Axcella Therapeutics to Participate in Piper Sandler 33rd Annual Healthcare Conference
11/18/2021
Axcella Therapeutics to Participate in Piper Sandler 33rd Annual Healthcare Conference.
-
Axcella Therapeutics Reports Third Quarter Financial Results and Provides Update on Long COVID, OHE and NASH Clinical Trials
11/10/2021
Axcella Therapeutics today announced financial results for the third quarter ended September 30, 2021 and provided a business update.
-
Axcella Therapeutics Announces Upcoming Presentations at AASLD’s The Liver Meeting® 2021
11/2/2021
Axcella Therapeutics today announced two upcoming poster presentations at The Liver Meeting® 2021, the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), which is taking place virtually November 12-15, 2021.
-
Clinical Catch-Up: October 25-29
11/1/2021
Yet another busy week for clinical trial news. Here’s a look. -
Axcella announced it is initiating a new clinical program to study AXA1125 in patients with Long Covid. The trial will be conducted at the Oxford Centre for Clinical Magnetic Resonance Research.
-
Axcella, Now Axcella Therapeutics, to Host Virtual R&D Day on October 26, 2021
10/19/2021
Axcella Therapeutics today announced that it will host a virtual R&D Day on Tuesday, October 26, 2021, at 10:00 a.m. ET.
-
Axcella Announces Upcoming Investor Conference Presentation - Oct 05, 2021
10/5/2021
Axcella, a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator compositions, announced that management will be presenting at the H.C. Wainwright 5th Annual NASH Investor Conference.
-
Axcella Announces Upcoming Investor Conference Presentation - Sep 07, 2021
9/7/2021
Axcella, a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator compositions, announced that management will be presenting at the H.C. Wainwright 23rd Annual Global Investment Conference.
-
Clinical Catch-Up: August 16-20
8/23/2021
It was another busy week in clinical trial news. Here’s a look. -
Axcella Announces Publication in The American Journal of Gastroenterology of Positive Results from AXA1125-003 in Subjects With Presumed NASH
8/16/2021
Axcella today announced the publication of results from the company’s AXA1125-003 clinical study in The American Journal of Gastroenterology
-
Axcella Reports Second Quarter Financial Results and Provides Business Update
7/29/2021
Axcella, a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator compositions, announced financial results for the second quarter ended June 30, 2021 and provided a business update.